Immunomedics, Inc., a New Jersey-based biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, recently announced that the company was awarded U.S. Patent 7,662,378 for its antibody therapy.
The patent covers the use of humanized, chimeric or human antibodies that bind to the carcinoembryonic antigen (CEA) in combination with at least one other therapeutic agent. The allowed claims also cover methods of treating CEA-expressing cancers, including certain types of thyroid cancer, colorectal cancers, gastric cancer, lung cancer and breast cancer.
Cynthia L. Sullivan, president and chief executive officer of Immunomedics, Inc., stated, “This is another important patent protection around our family of anti-CEA antibodies until the year 2023. TF2, a new bi-specific antibody construct containing the anti-CEA antibody, is currently in three investigator-sponsored clinical studies in the U.S. and Europe for pretargeted imaging and radioimmunotherapy of colorectal and lung cancers.” Ms. Sullivan continued, “Our humanized anti-CEA antibody labeled with therapeutic doses of I-131 has also been reported, in a Phase-II study published from Germany, to extend the survival of colorectal cancer patients who had resection of their liver metastases.”
Immunomedics currently has a portfolio of intellectual property, which includes approximately 146 patents issued in the United States and more than 300 other patents issued worldwide.